13 results about "Viral antigen" patented technology

A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.

The invention refers to a dumbbell-shaped DNA vector comprising a transcriptional promoter, a sequence for expressing an RNA, and a transcriptional terminator The sequence for expressing an RNA may be selected from the group consisting of an ornithine transcarbamylase, a phenylalanine hydroxylase (PAH), and a viral antigen.

This invention discloses a blow-type sampling viral antigen detection kit and its usage method, including a sampler, a blow nozzle, a detection working column, and a equilibration liquid dropper. Sampling is performed by blowing air, a simple sampling method that reduces the probability of sampling errors in untrained individuals. Equilibration liquid is dripped into the funnel-shaped opening of the sampler's receiving tank through the equilibration liquid dropper, continuously eluting the biological sample. The operation is simple and effective. The equilibration liquid, along with the eluted biological sample, enters a colloidal gold filter. The colloidal gold is re-dissolved, captures and labels the viral antigen in the solution. The labeled antigen then enters an antibody filter impregnated with specific antibodies, where it is captured by those antibodies, forming a conjugate of antibody, antigen, and colloidal gold microparticles. A large number of these conjugate microparticles aggregate on the filter membrane above the absorbent cotton column, resulting in color development. The sample elution step is simple, the sampling method is reliable, and the detection and colorimetric observation are easy to perform, making it convenient for the general public to use.

The application discloses an epitope tandem polypeptide of porcine reproductive and respiratory syndrome and related biological materials and application thereof, and belongs to the field of viral antigen vaccines or biomedical technologies. The application provides an epitope tandem polypeptide which is composed of neutralizing antigen epitopes, Th epitopes and CTL epitopes of multiple structural proteins and non-structural proteins of PRRSV in series, and includes PNB, PTH and PCTL. The epitope tandem polypeptide provided by the application can be directly used for preparing a subunit vaccine of PRRSV, and has the advantages of simple preparation method, strong immunogenicity and good safety. The epitope tandem polypeptide can also be combined with an inactivated vaccine of PRRSV and applied to enhance cellular immunity induced by the inactivated vaccine, so that the epitope tandem polypeptide can more effectively prevent and protect pigs from PRRSV infection. The epitope tandem polypeptide composition contains common epitope sequences of seven representative strains (LV, VR-2332, CH-1a, JXA1, NADC30, NADC34 and RFLP 1-4-4) of PRRSV, and is expected to have good cross-protection for infection of different strains.

The strip systems, methods, devices and associated kits disclosed herein are used to determine the presence and / or level a target analyte(s) in sample (e.g., a biological sample such as saliva or nasal swab) wherein the target analyte(s) may be a microorganism (e.g., a whole virus) or molecule (e.g., a viral antigen) associated with a healthy state, disease or injury or otherwise altered physiological condition. In certain embodiments, the systems, methods, devices and kits provide one or more improved properties relative to the lateral flow protein and other assays known in the art for the detection, including but not limited to, assay time, ease of use, risk of infection, accuracy, specificity, selectivity, limit of detection of the assay, quantitative detection and the effect of common interferents to the sensor output, cost, simplicity or a combination thereof. In certain embodiments, the systems, assays, methods and kids are multiplexed, i.e., permit detection or monitoring of more than one target analyte (e.g., two different viruses or a virus and a bacterium).

The application discloses a shark-derived single-domain antibody binding SARS-CoV-2 RBD, the amino acid sequence of the single-domain antibody is shown as SEQ ID NO: 2 or SEQ ID NO: 4; nucleotides encoding the above-mentioned shark-derived single-domain antibody, characterized in that the nucleotide sequence is shown as SEQ ID NO: 1 or SEQ ID NO: 3; the application also provides a preparation method of the shark-derived single-domain antibody binding SARS-CoV-2 RBD, and the shark-derived single-domain antibody is obtained by sequentially performing immunization, constructing a phage antibody library, screening positive clones from the phage antibody library, finally adding an inducer for expression after large-scale culture, and collecting and purifying antibody proteins; the shark-derived single-domain antibody prepared by the application has good application prospects in the development of a new coronavirus disinfecting spray and a new coronavirus antigen detection kit.

Early Nasopharyngeal Carcinoma (NPC) detection methods, devices, and kits are provided utilizing novel Epstein-Barr Virus (EBV) EBNA1 antigens to detect serum anti-EBNA1 IgA antibodies with superior correlation to NPC development within four years.

The present invention relates anti-microbial antibody signatures related to lung tumors, including benign tumors and adenocarcinomas. Disclosed herein are antibody panels comprising antigens from bacteria and / or viruses for use in early and accurate diagnosis of lung cancer and for reducing false positive lung carcinoma diagnoses from CT screening.

The invention discloses a self-replicating mRNA (messenger Ribonucleic Acid) vaccine for a Databan virus as well as a preparation method and application of the self-replicating mRNA vaccine, and belongs to the technical field The technical problem to be solved is to provide a high-immunogenicity self-replicating mRNA (messenger Ribonucleic Acid) vaccine for the DABV. According to the key point of the technical scheme, the antigen molecule consists of four parts: a signal peptide, a Databa virus glycoprotein, a connexon and MITD; the Databa virus glycoprotein is glycoprotein Gn with an amino acid sequence shown as SEQ ID NO: 1 or a glycoprotein precursor GP with an amino acid sequence shown as SEQ ID NO: 2. The self-replicating mRNA technology is applied to the virus for the first time, the antigen molecule is combined with the self-replicating mRNA vector, and lasting immunization and cross protection can be realized with an ultralow dosage of less than or equal to 5 mu g at a single time; the antibody still keeps high antibody titer after 24 weeks, the challenge test shows excellent performance, and long-term immune memory lays a foundation for clinical application.

The invention relates to antisense molecules and methods for modulating splicing of polyomavirus T antigen pre-mRNA. In one aspect the invention relates to an antisense oligonucleotide 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length which comprises a sequence that is the reverse complement of a contiguous stretch of at least 12 nucleobases of a polyomavirus T-antigen pre-mRNA and which antisense oligonucleotide can modulate splicing of said T-antigen pre-mRNA in a cell.

This invention discloses a method for preparing Akabane virus vaccine based on BEI inactivation and its application. This invention optimizes the BEI inactivation process for the AKAV_FS202301 Akabane virus strain, ensuring complete virus inactivation while effectively preserving the viral antigen structure. The prepared inactivated vaccine can induce high titers of neutralizing antibodies in experimental animals; specifically, the neutralizing antibody titer in rabbit immune serum is 5. 6 The neutralizing antibody titer in mouse immune serum was 5. 5 The obtained immune serum significantly reduced the viral RNA copy number of AKAV, inhibited viral replication activity, and significantly reduced the proportion of AKAV-infected positive cells. In summary, the Akabane virus vaccine provided by this invention achieves highly efficient antigen retention and significantly enhanced immune response, possessing advantages such as strong immunogenicity and significant viral inhibition effect, and has promising application prospects.

The application discloses a kind of based on single-domain antibody 9-4-1 immunomagnetic bead direct spread detection small ruminant pestivirus kit and its application.The kit includes the single-domain antibody 9-4-1 immunomagnetic bead obtained by the single-domain antibody 9-4-1 shown in SEQ ID NO.1 small ruminant pestivirus through streptavidin-biotin and magnetic bead coupling.The single-domain antibody 9-4-1 protein purified by gel cutting is coupled with magnetic bead to obtain immunomagnetic bead, after small ruminant pestivirus is enriched by immunomagnetic bead, it can be directly amplified without extracting genomic RNA.The application overcomes the problems of low virus content, low detection rate, easy to miss detection, etc.;And a series of problems such as time-consuming, costly, laborious, environmental pollution during operation when extracting genomic RNA, by directly amplifying enrichment product, not only save time, save resources, but also efficient, sensitive, specific, stable, the application provides a kind of efficient technical means for small ruminant pestivirus antigen detection.

The application provides an immunological kit, antibodies and biological materials for detecting SFTSV-NP antigen, belongs to the technical field of immunological detection, and a pair of new monoclonal antibodies for the NP antigen of the new Bunyavirus is obtained through a hybridoma technology, including a coating antibody and a detection antibody; the high affinity and high specificity of the new Bunyavirus NP protein are verified through Western Blot, so that the preparation of a double-antibody sandwich ELISA detection kit for the NP antigen of the new Bunyavirus can be realized, and a detection kit with higher detection accuracy can be obtained.